OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.
Tag Archives: Clinical
Cara Therapeutics has been phenomenal over the past couple of years, and it’s rightfully beginning to catch the attention of marijuana stock investors.
HOBART, May 24, 2017 /Weed Wire/ — It is important to correct misleading claims made by the Greens yesterday that access to unregistered medical cannabis products will be restricted under the Controlled Access Scheme (CAS).
NEW YORK, May 24, 2017 /Weed Wire/ – After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency 39 percent for patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical trial for the compound.
HOBART, May 23, 2017 /Weed Wire/ — The Hodgman Liberal Government is supporting Tasmanians to get access to medical cannabis through the Controlled Access Scheme from September 1.
PHOENIX, March 17, 2017 /Weed Wire/ — As of March 15, 2017, five participants have received marijuana (cannabis) provided by the National Institute on Drug Abuse (NIDA) in an ongoing Phase 2 clinical trial sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) at the Scottsdale Research Institute (SRI) in Phoenix, Ariz. MAPS is committed to sponsoring rigorous clinical research to develop cannabis into a prescription medicine through the Food and Drug Administration (FDA).
DEVON, Penn., March 13, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.
With its Humboldt Institute for Interdisciplinary Marijuana Research, Humboldt State University in California has been at the academic forefront of marijuana since 2012, but other institutions of higher education in the state are starting to follow suit.
Whenever medical marijuana is mentioned, the image of people with chronic pain and other painful illnesses comes to mind. The mainstream image of medical marijuana is that it can help treat pain, nausea, and even epileptic seizures.